A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma.

CONCLUSION: Sequential irinotecan and flavopiridol are ineffective and poorly tolerated in patients with advanced HCC. Despite our limited assessments, it is possible that the presence of wild-type p53 is necessary but not sufficient to predict response in HCC. PMID: 23293699 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research